“The over-arching purpose of these enhancements to Preclarus and our technology platform is to improve the user experience for our clients and investigative sites,” said Christopher Fikry, MD, executive vice president, PPD Laboratories.
“The new Preclarus lab data portal creates a secure access point for study sponsors to oversee their PPD central lab trial performance and analyze lab results,” he told us.
Enhancements include various new functionalities for logistics support and supply chain, as well as sample storage, informed consent, and reporting.
The contract research organization (CRO) also has launched a new mobile app for its Preclarus investigator site portal, which Fikry said “helps busy investigators and site coordinators manage their PPD central lab trials from the convenience of their mobile devices.”
The app is available for download on iOS and Android devices.
PPD’s Accelerated Enrollment Solutions business unit, which includes Acurian and Synexus, also this month launched a new site solution for enrolling patients in clinical studies.
The new offering, SynexusPlus, collates all recruitment, site, investigator grant, and other fees from Acurian and Synexus into a single price per patient.
Additionally, PPD recently introduced a new patient enrollment model, PatientAdvantage.
The new approach inverts the traditional clinical trial delivery steps by first, identifying potential participants before delivering qualified patients to investigative sites for enrollment, according to the CRO.